# HIV/AIDS Clinical Advisory Group (CAG)

Douglas G. Fish, MD

Medical Director, Division of Program Development

& Management

Office of Health Insurance Programs

Lindsay Cogan, PhD, MS

Director, Division of Quality Measurement

Office of Quality and Patient Safety

## Agenda

1. Introduction 15 min

2. National Quality Measurement Updates 5 min

3. New York State (NYS) Core Quality Measurement Strategy 35 min

4.Summary and Next Steps 5 min



#### Section 1: Introduction

Quadruple Aim in Health Care Clinical Advisory Group (CAG) 2018 Timeline & Expectations VBP Quality Measure Integration Timeline 2017 HIV/AIDS VBP Arrangement Summary Recap: Risk Stratification for VBP Measures



#### United we Stand!

 The HIV/AIDS Value Based Payment Clinical Advisory group is now officially merged with the AI's HIV Quality Advisory Committee!!



#### Triple Aim → Quadruple Aim in Health Care

Clinician
Wellness /
Increasing
Provider
Satisfaction &
Reducing Burden

Improving
Patient
Experience of
Care
(Satisfaction &
Quality)

Reducing Health
Care Per Capita
Costs

Improving
Clinical
Outcomes in
Population



#### Addressing Provider Burnout

Some Good News: Provider burnout down 9% from 2017 to 42% of respondents reporting burnout. However, approximately 15% admitted to experiencing either clinical or colloquial forms of depression. – AMA Wire, August 3, 2018

#### **Leading Causes of Provider Burnout**

- Physicians claims of too many bureaucratic tasks
- Less than desirable work schedule/ hours
- Lack of respect from patients
- Attitudes of colleagues
- Depression

## Solutions & Ways VBP addresses *Provider* Burnout

- Developing and implementing workforce redesign strategies reduces administrative burden for those on the front lines including LMSW's, LCSW's, Nurse Practitioners of Psychiatry and Psychiatrists in Behavioral Health, and, Nurses, Nurse Practitioners and Physicians, and for all those in direct service.
- Adoption of Wellness programs.
- Seeking out new opportunities for education/professional growth.
- Limiting social isolation in work; increasing opportunities for social connectedness to combat increased time spent in documentation.



#### Clinical Advisory Group (CAG) 2018 Timeline & Expectations

#### 2018 CAG Goals

- Conduct annual review of the quality measure sets
- Identify and analyze clinical and care delivery gaps in current measure sets
- Propose recommendations for 2019

#### **Timeline**

- CAGs convene in spring and summer.
- Based on CAG feedback, the State will present the proposed measure set to the Value Based Payment (VBP)
   Workgroup for approval in October
- The final Measurement Year (MY) 2019 Quality Measure Sets will be released in October/ early November.
- The MY 2018 VBP Reporting Requirements Technical Specifications Manual will be released in October/early November.



#### VBP Quality Measure Integration Timeline

Summary of 2017 Measure Readiness by VBP Measure Set

In February of 2017, a total of **76** unique quality measures were approved by the VBP Workgroup for further review and incorporation into the 2017 VBP Program. Of the unique measures approved by the VBP workgroup, the following were approved for reporting as Category 1 (Cat 1) or Category 2 (Cat 2) in 2017 through the following VBP arrangements:

#### HIV/AIDS Measure Set (44 Total Measures)

- 10 measures unique to the HIV/AIDs Arrangement
- 34 measures that are also included in the TCGP/IPC Arrangement

#### HARP Measure Set (41 Total Measures)

- 9 measures unique to the HARP Arrangement
- 32 measures that are also included in the TCGP/IPC Arrangement

#### TCGP/IPC Measure Set (40 Total Measures)

- 5 measures are unique to the TCGP/IPC Arrangements
- 35 measures are shared with at least one of the other measure sets.

#### Maternity Care Measure Set (18 Total Measures)

- 17 measures unique to the Maternity Care Arrangement
- 1 measure that is also included in the TCGP/IPC Arrangement



# 2017 HIV/AIDS VBP Arrangement Summary

| 2017<br>HIV/AIDS VBP   | 2017 Measure Feasibility Review |                       |                      | Anticipated Integration Into Reportable Set of NYS |                       |            |            |                                |
|------------------------|---------------------------------|-----------------------|----------------------|--|-----------------------|------------|------------|--------------------------------|
| Quality<br>Measure Set | Feasible in                     | 2017                  | Not Feasible in 2017 |  | VBP HIV/AIDS Measures |            |            |                                |
| Measure Set<br>Total*  | All Measures                    | Unique to<br>HIV/AIDS | All Measures         | Unique to<br>HIV/AIDS                              | 2018                  | 2019       | 2020       | Integration<br>Date<br>Unknown |
| 44                     | 20/44                           | 1/10                  | 24/44                | 9/10   | +3                    | +6         | +11        | 4                              |
|                        |                                 |                       |                      |  | (0 unique)            | (2 unique) | (7 unique) | (0 unique)                     |
| Category 1             |                                 |                       |                      |  |                       |            |            |                                |
| P4P                    | 14/17                           | 1/2                   | 3/17                 | 1/2  | 2                     | 0          | 0          | 0                              |
| P4R                    | 4/13                            | 0/2                   | 9/13                 | 2/2  | 1                     | 1          | 5          | 0                              |
| Category 2             | Category 2                      |                       |                      |  |                       |            |            |                                |
|                        | 2/14                            | 0/6                   | 12/14                | 6/6  | 0                     | 5          | 6          | 4                              |

<sup>\*34</sup> measures within the set are also included in the TCGP/IPC Measure Set



# HIV/AIDS VBP Arrangement Anticipated Measure Integration (1/2)

| Total New<br>Measures |  |   |   |              |
|-----------------------|--|---|---|--------------|
| Category 1            | Measures   |   |   |              |
| P4P                   |  | Adherence to Mood Stabilizers for<br>Individuals with Bipolar I Disorder                  | -   | -            |
|                       | Controlling High Blood Pressure  | -   | -   | <u>-</u>     |
|                       | Potentially Avoidable<br>Complications in Routine Sick Care<br>or Chronic Care | Preventive Care and Screening:<br>Body Mass Index (BMI) Screening<br>and Follow – Up Plan | Preventive Care and Screening:<br>Influenza Immunization                                  | -            |
|                       | -  | -   | Preventive Care and Screening:<br>Screening for Clinical Depression<br>and Follow–Up Plan | -            |
| P4R                   | -  | -   | Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention          | <del>-</del> |
|                       |  |   | Substance Abuse Screening   |              |
|                       | -  | -   | Comprehensive Diabetes Care: Foot Exam  | <del>-</del> |

# HIV/AIDS VBP Arrangement Anticipated Measure Integration (2/2)

| Total New<br>Measures |   |   |  |
|-----------------------|---|---|--|
| Category 2 Measures   |   |   |  |
| -                     | Initiation of Pharmacotherapy upon<br>New Episode of Alcohol Abuse or<br>Dependence | Sexually Transmitted Diseases:<br>Screening for Chlamydia, Gonorrhea,<br>and Syphilis | Asthma: Assessment of Asthma<br>Control – Ambulatory Care Setting                      |
| -                     | Continuing Engagement in Treatment (CET) Alcohol and other Drug Dependence          | Diabetes Screening (HIV/AIDS)   | Continuity of Care from Inpatient<br>Detox or Inpatient Care to Lower<br>Level of Care |
| -                     | Use of Opioid Dependence<br>Pharmacotherapy   | Hepatitis C Screening   | Patient Self-Management and Action<br>Plan (Asthma)                                    |
| -                     | Linkage to HIV Medical Care   | Housing Status  | Lung Function/Spirometry Evaluation (Asthma)   |
|                       | Prescription of HIV Antiretroviral Therapy  | Sexual History Taking: Anal, Oral, and Genital (HIV/AIDS)                             |  |
| -                     |   | Medical Case Management: Care<br>Plan   |  |



#### Recap: Risk Stratification for VBP Measures

- NYS DOH is <u>not</u> holding providers to a benchmark standard and there are no comparisons being made between providers <u>by the State</u> on such a basis for Value Based Payment.
- NYS DOH VBP Quality Measurement program compares a provider organization (VBP contractor) to itself, not to other health care providers/systems, i.e., VBP measures you against your baseline performance.
- However, providers may apply different thresholds for passing a measure(s) to a population or a site viewed as higher risk, as negotiated with the Managed Care Organization.



# Section 2: National Quality Measurement Updates

Chronic Pulmonary, Heart, Diabetes and Primary Care Mental Health and Substance Use



#### National Quality Measurement Updates

#### **Chronic Pulmonary, Heart, Diabetes and Primary Care**

#### **HEDIS 2019**

- Measure Change Controlling High Blood Pressure
  - Update the blood pressure target to <140/90 mm Hg for all hypertensive patients 18–85 years of age.
  - Remove the medical record confirmation requirement and use two outpatient encounters to identify the denominator.
  - Add administrative numerator specifications.
  - Allow use of telephone, videoconferencing, and asynchronous telehealth encounters to satisfy one of two required outpatient visits in the denominator.
  - Allow remote monitoring device readings directly transmitted to and interpreted by the provider to satisfy the numerator.



# Section 3: NYS Quality Measurement Strategy

Quality Measure Prioritization: Goals for 2018 Measure Set Review
MY 2018 VBP HIV/AIDS Measure Set
Recommended MY 2019 HIV/AIDS VBP Measure Set
Measures Recommended for Removal from the HIV/AIDS VBP Measure Set in 2019
Tentative Measures for Inclusion in the MY 2019 VBP HIV/AIDS Measure Set

# Quality Measure Prioritization: Goals for 2018 Measure Set Review

- Prioritize a focused list of high value quality measures for VBP in MY 2019.
- Key Principles in measure prioritization:
  - Process → Outcome;
  - Gather feedback from stakeholders on what are the "right" outcomes; and
  - Focus on efficient measurement
- Align quality measurement efforts across stakeholder communities and State and Federal-led quality programs.
- Reduce the number of measures in use for VBP to focus on a core set and minimize administrative burden for providers where possible.
- Focus on measures compiled from clinical, rather than claims, data to allow for feedback loops from the measure back into clinical decision making.

#### Recommended HIV/AIDS VBP Priority Measures

| Priority HIV/AIDS Measure  | Category  | Claims Based | Non Claims Based   |  |  |  |  |  |
|--|-----------|--------------|--|--|--|--|--|--|
| Outcome / Intermediate Outcome Measures  |           |              |  |  |  |  |  |  |
| Comprehensive Diabetes Care: Hemoglobin A1c (HbA1c) Poor Control (>9.0%)             | Cat 1     | No           | Claims, Electronic Health Data,<br>Electronic Health Records, Paper<br>Medical Records |  |  |  |  |  |
| Controlling High Blood Pressure  | Cat 1     | No           | E.H.R., CMS Web Interface  |  |  |  |  |  |
| Depression Remission Response for Adolescents and Adults                             | Cat 2 (?) | No           | -  |  |  |  |  |  |
| HIV Viral Load Suppression   | Cat 1     | No           | Hybrid measure, Medical Record Review  |  |  |  |  |  |
| Priority Evidence Based Process Measures   |           |              |  |  |  |  |  |  |
| Initiation and Engagement of Alcohol and Other Drug Abuse Dependence Treatment (IET) | Cat 1     | Yes          | -  |  |  |  |  |  |
| Medication Management for People with Asthma   | Cat 1     | Yes          | -  |  |  |  |  |  |

- These measures reflect proposed prioritization to the VBP TCGP/IPC measure set for MY 2019.
- HIV Viral Load Suppression has previously been agreed as a priority measure with this group.
- Earlier this year, the Behavioral Health CAG also recommended two key areas for prioritization:
  - 1. Adding the IET measure to address a lack of outcome measures for substance abuse disorder; and
  - 2. Prioritizing depression outcome measures over screening for depression (no outcome measure currently included in the measure set).
- Is this the best list of measures to prioritize for the MY 2019 measure set?



### Measures Requiring Feedback - HIV/AIDS Measure Set (1/4)

We are seeking <u>additional specific feedback</u> regarding the MY 2018 measures below to determine whether to include them in the MY 2019 measure set. Questions for each measure are raised on the following slides.

| HIV/AIDS Measure  | Category | Classification | Measure Steward       | NQF Endorsed? |
|---|----------|----------------|-----------------------|---------------|
| Process Me  | asures   |                |                       |               |
| Linkage to HIV Medical Care   | Cat 2    | -              | NYS                   | No            |
| Substance Abuse Screening   | Cat 1    | P4R            | HRSA, HIV/AIDS Bureau | No            |
| Sexually Transmitted Diseases: Screening for Chlamydia, Gonorrhea, and Syphilis | Cat 2    | -              | NCQA                  | Yes           |



## Measures Requiring Feedback (2/4)

#### **Linkage to HIV Medical Care**

- Category 2
- Measure Steward: NYS; Not NQF endorsed
- Percentage of patients who attended a routine HIV medical care visit within 1 month of HIV diagnosis

Q: What timeframe should be used for this measure to align with eHIVQUAL specification? Should this measure remain as Category 2 if included in the MY 2019 measure set?



#### Measures Requiring Feedback (3/4)

#### **Substance Abuse Screening**

- Category 1, P4R
- Measure Steward: HRSA; Not NQF endorsed
- Percentage of new patients with a diagnosis of HIV who have been screened for substance use (alcohol & drugs) in the measurement year

Q: Do you agree with moving this measure to Category 2 because it is a one-time screening at diagnosis?



## Measures Requiring Feedback (4/4)

#### Sexually Transmitted Diseases: Screening for Chlamydia, Gonorrhea, and Syphilis

- Moved from Category 1 to Category 2 in 2018 due to focus on NYS annual screening
- Measure Steward: NCQA; NQF endorsed
- Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS, who have received chlamydia, gonorrhea, and syphilis screenings at least once since the diagnosis of HIV infection

Q: Do you agree with this measure being moved from Category 2 to Category 1 if we change to the NYS measure (annual screening) in the MY 2019 measure set?



# Measures Recommended for Removal from the HIV/AIDS VBP Measure Set in 2019

| HIV/AIDS Measure  | Category   | Classification | Measure<br>Steward | NQF Endorsed? |
|---|------------|----------------|--------------------|---------------|
| Outcome / Intermediate Outcome  | e Measures |                |                    |               |
| Comprehensive Diabetes Care: Hemoglobin A1c (HbA1c) Control (<8.0%)   | Cat 1      | P4R            | NCQA               | Yes           |
| Process Measures  |            |                |                    |               |
| Comprehensive Diabetes Care: All Three Tests (HbA1c, dilated eye exam, and medical attention for nephropathy) | Cat 1      | P4P            | NCQA               | Yes           |
| Comprehensive Diabetes Care: Foot Exam  | Cat 1      | P4R            | NCQA               | Yes*          |
| Comprehensive Diabetes Care: Hemoglobin A1c (HbA1c) testing [performed]                                       | Cat 1      | P4P            | NCQA               | Yes           |
| Statin Therapy for Patients with Diabetes   | Cat 1      | P4R            | NCQA               | No            |

- The measures above are <u>specifically recommended</u> for removal from the VBP HIV/AIDS measure set in 2019, and therefore would not be considered for inclusion in the prioritized list of measures.
  - Specific reasons for removal include that these measures are duplicative of the prioritized outcome measure for diabetes care.
- This also reflects proposed changes to the VBP TCGP/IPC measure set.
- Do you agree these measures should not be considered for the MY 2019 measure set?



#### MY 2018 VBP HIV/AIDS Measure Set (1/2)

| HIV/AIDS Measure  | Category | Classification | Measure Steward | NQF Endorsed? | MIPS Measure? |  |
|---|----------|----------------|-----------------|---------------|---------------|--|
| Outcome / Intermediate Outcome Measures   |          |                |                 |               |               |  |
| Comprehensive Diabetes Care: Hemoglobin A1c (HbA1c) Control (<8.0%)   | Cat 1    | P4R            | NCQA            | Yes           | N             |  |
| Comprehensive Diabetes Care: Hemoglobin A1c (HbA1c) Poor Control (>9.0%)                                      | Cat 1    | P4P            | NCQA            | Yes           | Υ             |  |
| Controlling High Blood Pressure   | Cat 1    | P4P            | NCQA            | Yes           | Υ             |  |
| HIV Viral Load Suppression  | Cat 1    | P4P            | HRSA            | Yes           | Υ             |  |
| Process Measures  |          |                |                 |               |               |  |
| Adherence to Mood Stabilizers for Individuals with Bipolar 1 Disorder   | Cat 1    | P4P            | CMS             | Yes           | N             |  |
| Antidepressant Medication Manage – Effective Acute Phase Treatment & Effective Continuation Phase Treatment   | Cat 1    | P4P            | NCQA            | Yes           | Y             |  |
| Breast Cancer Screening   | Cat 1    | P4P            | NCQA            | Yes           | Υ             |  |
| Cervical Cancer Screening   | Cat 1    | P4P            | NCQA            | Yes           | Υ             |  |
| Colorectal Cancer Screening   | Cat 1    | P4P            | NCQA            | Yes           | Υ             |  |
| Comprehensive Diabetes Care: All Three Tests (HbA1c, dilated eye exam, and medical attention for nephropathy) | Cat 1    | P4P            | NCQA            | Yes           | N             |  |
| Comprehensive Diabetes Care: Eye Exam (retinal) Performed)  | Cat 1    | P4P            | NCQA            | Yes           | Υ             |  |
| Comprehensive Diabetes Care: Foot Exam  | Cat 1    | P4R            | NCQA            | Yes           | Υ             |  |
| Comprehensive Diabetes Care: Hemoglobin A1c (HbA1c) testing [performed]                                       | Cat 1    | P4P            | NCQA            | Yes           | N             |  |
| Comprehensive Diabetes Care: Medical Attention for Nephropathy  | Cat 1    | P4P            | NCQA            | Yes           | Y             |  |
| Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications  | Cat 1    | P4P            | NCQA            | Yes           | N             |  |



#### MY 2018 VBP HIV/AIDS Measure Set (2/2)

| HIV/AIDS Measure  | Category | Classification | Measure Steward          | NQF Endorsed? | MIPS Measure? |  |
|---|----------|----------------|--------------------------|---------------|---------------|--|
| Process Measures  |          |                |                          |               |               |  |
| Initiation and Engagement of Alcohol and Other Drug Dependence Treatment                                  | Cat 1    | P4P            | NCQA                     | Yes           | Υ             |  |
| Initiation of Pharmacotherapy upon New Episode of Opioid Dependence                                       | Cat 1    | P4P            | NYS                      | No            | N             |  |
| Medication Management for People with Asthma (ages 5-64) – 50% and 75% of Treatment Days Covered          | Cat 1    | P4P            | NCQA                     | No            | Y             |  |
| Preventative Care and Screening: Body Mass Index (BMII) Screening and Follow-Up Plan                      | Cat 1    | P4R            | CMS                      | Yes           | Υ             |  |
| Preventive Care and Screening: Influenza Immunization   | Cat 1    | P4R            | AMA PCPI                 | Yes           | Υ             |  |
| Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan                       | Cat 1    | P4R            | CMS                      | Yes           | Υ             |  |
| Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention                          | Cat 1    | P4R            | AMA PCPI                 | Yes           | Υ             |  |
| Proportion of Patients with HIV/AIS that have a Potentially Avoidable Complication during a Calendar Year | Cat 1    | P4R            | Altarum Institute        | No            | N             |  |
| Stain Therapy for Patients with Cardiovascular Disease  | Cat 1    | P4R            | NCQA                     | No            | N             |  |
| Statin Therapy for Patients with Diabetes   | Cat 1    | P4R            | NCQA                     | No            | N             |  |
| Substance Abuse Screening   | Cat 1    | P4R            | HRSA, HIV/AIDS<br>Bureau | No            | N             |  |
| Use of Alcohol Abuse or Dependence Pharmacotherapy  | Cat 1    | P4R            | NYS                      | No            | N             |  |
| Use of Spirometry Testing in the Assessment and Diagnosis of COPD   | Cat 1    | P4R            | NCQA                     | Yes           | N             |  |
| Linkage to HIV Medical Care   | Cat 2    | -              | NYS                      | No            | N             |  |
| Sexually Transmitted Diseases: Screening for Chlamydia, Gonorrhea, and Syphilis                           | Cat 2    | -              | NCQA                     | Yes           | N             |  |

Acronyms: CMS = Centers for Medicare and Medicaid Services; NCQA = National Center for Quality Assurance; HRSA = Health Resources Services Administration; MY = Measurement Year; NYS = New York State.

NYS = New YORK State.

Note: This table only highlights specific Category 2 measures. For the complete 2018 HIV/IAIDS VBP Measure Set, please see the NYS DOH VBP website (<u>Link</u>).



#### **Next Steps**

- Please provide any feedback on the evolving HIV/AIDS Quality Measure set and send suggestions or recommendations.
- Provide any additional feedback/recommendations to Matthew Reuter at matthew.reuter@health.ny.gov by Monday, September 24, 2018.
- Recommendations will go the final approving body, the VBP Workgroup in early October.
- The final Measurement Year (MY) 2019 Quality Measure Sets will be released in October/early November.
- The MY 2018 VBP Reporting Requirements Technical Specifications Manual will be released in October/early November.



# Thank you!